A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
J A Chan, L S Blaszkowsky, P C Enzinger, D P Ryan, T A Abrams, A X Zhu, J S Temel, D Schrag, P Bhargava, J A Meyerhardt, B M Wolpin, P Fidias, H Zheng, S Florio, E Regan, C S Fuchs, J A Chan, L S Blaszkowsky, P C Enzinger, D P Ryan, T A Abrams, A X Zhu, J S Temel, D Schrag, P Bhargava, J A Meyerhardt, B M Wolpin, P Fidias, H Zheng, S Florio, E Regan, C S Fuchs
Abstract
Background: Epidermal growth factor receptor (EGFR) is overexpressed in a significant proportion of esophageal and gastric carcinomas. Although previous studies have examined tyrosine kinase inhibitors of EGFR, there remains limited data regarding the role of EGFR-directed monoclonal antibody therapy in these malignancies. We carried out a multi-institutional phase II study of cetuximab, a monoclonal antibody against EGFR, in patients with unresectable or metastatic esophageal or gastric adenocarcinoma.
Patients and methods: Thirty-five patients with previously treated metastatic esophageal or gastric adenocarcinoma were treated with weekly cetuximab, at an initial dose of 400 mg/m(2) followed by weekly infusions at 250 mg/m(2). Patients were followed for toxicity, treatment response, and survival.
Results: Treatment with cetuximab was well tolerated; no patients were taken off study due to drug-related adverse events. One (3%) partial treatment response was noted. Two (6%) patients had stable disease after 2 months of treatment. Median progression-free survival and overall survival were 1.6 and 3.1 months, respectively.
Conclusion: Although well tolerated, cetuximab administered as a single agent had minimal clinical activity in patients with metastatic esophageal and gastric adenocarcinoma. Ongoing studies of EGFR inhibitors in combination with other agents may define a role for these agents in the treatment of esophageal and gastric cancer.
Figures
Source: PubMed